-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MK-3795 in Von Hippel-Lindau Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-3795 in Von Hippel-Lindau Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-3795 in Von Hippel-Lindau Syndrome Drug Details: MK-3795 is under development...
-
Product Insights
NewHypoxia Inducible Factor 2 – Drugs In Development, 2024
The Hypoxia Inducible Factor 2 pipeline drugs market research report outlays comprehensive information on the Hypoxia Inducible Factor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Cardiovascular, Genetic Disorders, and Undisclosed which include indications of Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Pulmonary Arterial Hypertension, Von Hippel-Lindau Syndrome, and Unspecified Rare Disease. It also reviews...
-
Product Insights
NewMacrophage Stimulating Protein Receptor – Drugs In Development, 2024
The Macrophage Stimulating Protein Receptor pipeline drugs market research report outlays comprehensive information on the Macrophage Stimulating Protein Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, and Genetic Disorders which include indications of Breast Cancer, Pancreatic Cancer, and Neurofibromatoses Type I (Von Recklinghausen's Disease). It also reviews key players involved in Macrophage Stimulating Protein Receptor...
-
Product Insights
NewCoagulation Factor VIII – Drugs In Development, 2024
The Coagulation Factor VIII pipeline drugs market research report outlays comprehensive information on the Coagulation Factor VIII targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Hematological Disorders, Cardiovascular, Central Nervous System, and Infectious Disease which include indications of Hemophilia A (Factor VIII Deficiency), Von Willebrand Disease (vWD), Venous Thromboembolism, Acute Ischemic Stroke, Alzheimer's Disease, Amyotrophic Lateral Sclerosis,...
-
Product Insights
NewAlkaline Phosphatase – Drugs In Development, 2024
The Alkaline Phosphatase pipeline drugs market research report outlays comprehensive information on the Alkaline Phosphatase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Genetic Disorders, Dermatology, Cardiovascular, and Gastrointestinal which include indications of Hypophosphatasia, Neurofibromatoses Type I (Von Recklinghausen's Disease), Burns, Pseudoxanthoma Elasticum (PXE or Gronblad Strandberg Syndrome), Atherosclerosis, Ischemia Reperfusion Injury, Ulcerative Colitis, and Celiac Disease....
-
Product Insights
NewMitogen Activated Protein Kinase 3 – Drugs In Development, 2024
The Mitogen Activated Protein Kinase 3 pipeline drugs market research report outlays comprehensive information on the Mitogen Activated Protein Kinase 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Genetic Disorders, and Cardiovascular which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Psoriasis, Neurofibromatoses Type I (Von Recklinghausen's Disease), and Hypertension. It also reviews...
-
Product Insights
NewTyrosine Protein Kinase Lck – Drugs In Development, 2024
The Tyrosine Protein Kinase Lck pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase Lck targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Respiratory, Oncology, Infectious Disease, and Genetic Disorders which include indications of Idiopathic Pulmonary Fibrosis, Interstitial Lung Fibrosis, Breast Cancer, Cervical Cancer, Influenzavirus A Infections, Coronavirus Disease 2019 (COVID-19) Pneumonia, Von...
-
Product Insights
NewCytotoxic T Lymphocyte Protein 4 – Drugs In Development, 2024
The Cytotoxic T Lymphocyte Protein 4 pipeline drugs market research report outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Infectious Disease, and Genetic Disorders which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Rheumatoid Arthritis, Graft Versus Host Disease (GVHD), Epstein–Barr Virus (HHV-4) Infections,...
-
Product Insights
NewEndothelial PAS Domain Containing Protein 1 – Drugs In Development, 2024
The Endothelial PAS Domain Containing Protein 1 pipeline drugs market research report outlays comprehensive information on the Endothelial PAS Domain Containing Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Cardiovascular, Genetic Disorders, and Undisclosed which include indications of Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Pulmonary Arterial Hypertension, Von Hippel-Lindau Syndrome, and Unspecified Rare...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rondaptivon Pegol in Arteriosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rondaptivon Pegol in Arteriosclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rondaptivon Pegol in Arteriosclerosis Drug Details: Rondaptivon pegol (BT-200) is under...